Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Change in Cash (2016 - 2025)

Historic Change in Cash for Summit Therapeutics (SMMT) over the last 10 years, with Q3 2025 value amounting to -$59.3 million.

  • Summit Therapeutics' Change in Cash fell 19077.5% to -$59.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $144.8 million, marking a year-over-year increase of 10592.41%. This contributed to the annual value of $33.8 million for FY2024, which is 10584.95% up from last year.
  • Per Summit Therapeutics' latest filing, its Change in Cash stood at -$59.3 million for Q3 2025, which was down 19077.5% from $86.3 million recorded in Q2 2025.
  • In the past 5 years, Summit Therapeutics' Change in Cash ranged from a high of $526.6 million in Q4 2022 and a low of -$577.6 million during Q1 2023
  • Moreover, its 5-year median value for Change in Cash was $1.2 million (2021), whereas its average is $9.1 million.
  • Its Change in Cash has fluctuated over the past 5 years, first surged by 632722.01% in 2022, then tumbled by 1030742.18% in 2023.
  • Summit Therapeutics' Change in Cash (Quarter) stood at -$8.5 million in 2021, then surged by 6327.22% to $526.6 million in 2022, then tumbled by 90.96% to $47.6 million in 2023, then plummeted by 76.72% to $11.1 million in 2024, then tumbled by 634.91% to -$59.3 million in 2025.
  • Its Change in Cash stands at -$59.3 million for Q3 2025, versus $86.3 million for Q2 2025 and $106.7 million for Q1 2025.